URGO SA
27.9 FTEURGO reported revenue of €16.8m for the 2025 financial year (annual accounts filed with the NBB on 08 May 2026), with 27.9 full-time equivalents.
The score of URGO shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +68 % Equity +30 % Total assets +244 % Headcount (avg FTE) +47 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
URGO's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 May 2026
- Year ended 31 Dec 2024filed on 20 May 2025
- Year ended 31 Dec 2023filed on 29 May 2024
- Year ended 31 Dec 2022filed on 02 May 2023
- Year ended 31 Dec 2021filed on 23 May 2022
URGO's financial analysis
- Solvency13.8%sector median: 28.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of URGO
URGO's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0474.339.007
- VAT number
- BE0474339007
- Peppol
- Registered · 0208:0474339007 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 15 Mar 2001
- Registered office
- 1180 Uccle
- Size
- Small · 27.9 FTE
- Latest accounts
- 2025 · filed on 08 May 2026
- Activity
- Activities of agents involved in non-specialised wholesale (NACE 46190)
URGO (SA) has been based in Uccle since 2001, active in: activities of agents involved in non-specialised wholesale. For 2025, it reports revenue of €16.8m, a net profit of 237,137 € and equity of €2.36m. With 27.9 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 13.8%, below the median of its sector (28.5%).
Companies similar to URGO
Companies in the same business, of comparable size and area, outside its group.
- S.A Therabel-Pharma N.V. Wholesale of pharmaceutical and medical goods Forest · balance sheet €12.8m
- Coloplast Belgium Wholesale of pharmaceutical and medical goods Beersel · balance sheet €16.8m
- BIOCODEX Benelux Wholesale of pharmaceutical and medical goods Forest · balance sheet €8.15m
- Bofar Wholesale of pharmaceutical and medical goods Wingene · balance sheet €12.2m
- Fagron Belgium Wholesale of pharmaceutical and medical goods Nazareth-De Pinte · balance sheet €7.86m
- DE Ceunynck Medical Wholesale of pharmaceutical and medical goods Aartselaar · balance sheet €16.9m
- Biogen Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €25.5m
- Thea Pharma Wholesale of pharmaceutical and medical goods Ghent · balance sheet €16.7m
Frequently asked questions about URGO
What is the revenue of URGO?
According to the 2025 annual accounts filed with the NBB, the revenue of URGO amounts to 16,808,093 €.
What is the VAT number of URGO?
In Belgium, the VAT number is the company number prefixed with BE: BE0474339007 for URGO, if the company is VAT-registered. Its company number (CBE) is 0474.339.007.
Where is the registered office of URGO?
According to the CBE register, the registered office of URGO is in 1180 Uccle.
What is the equity of URGO?
At the close of the 2025 financial year, the equity of URGO amounts to 2,359,256 €, a solvency of 13.8% of total assets.
How many people work at URGO?
27.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages URGO?
The register lists 6 active mandates at URGO. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of URGO
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →